Skip to main content

Junshi Bio Says PD-1 Meets Endpoints in Esophageal Cancer

Shanghai Junshi Biosciences stopped the Phase III trial of its anti-PD-1 candidate early because toripalimab met its survival endpoints at an interim review. Toripalimab was administered together with paclitaxel/cisplatin as a first-line treatment for patients with advanced esophageal squamous cell carcinoma. The combination met the pre-specified primary endpoints of Progression Free Survival and Overall Survival in a double-blind Phase III trial. Toripalimab is already approved for three other indications in China. More details... Stock Symbols: (HK: 1877; SHA: 688180) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.